DNA damage response and prostate cancer: defects, regulation and therapeutic implications

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• The DNA damage response (DDR) is crucial for maintaining genomic integrity in both normal and cancer cells.
• Prostate cancer progression involves mutations in DDR genes (e.g., BRCA1/2, P53) and activation of oncogenic signaling pathways (e.g., Akt, c-Myc), leading to genomic instability.
• These alterations can sensitize prostate cancer cells to specific DDR pathway inhibitors.

Purpose of the Study:

• To review DDR defects in prostate cancer during disease progression.
• To summarize recent advances in understanding DDR regulation in prostate cancer.
• To present therapeutic strategies involving combined targeting of DDR pathways.

Main Methods:

• Review of existing literature on DNA damage response in prostate cancer.
• Analysis of genetic mutations and signaling pathway activations in prostate cancer progression.
• Exploration of therapeutic vulnerabilities and combination strategies.

Main Results:

• Prostate cancer cells exhibit specific DDR defects that are exacerbated during progression.
• Androgen receptor (AR) plays a key regulatory role in DDR genes.
• Targeting DDR pathways (e.g., PARP, Chk1) offers potential for synthetic lethality or synergistic cytotoxicity.

Conclusions:

• Combining DNA-damaging agents or DDR inhibitors with AR-targeted therapies may be effective for aggressive prostate cancer.
• Understanding DDR defects and regulation is critical for developing novel therapeutic approaches.
• Targeting intact DDR components in combination strategies presents promising avenues for treatment.